Key Highlights

• Skyrizi Eclipses Humira: Skyrizi hit $4.5 billion in Q1 2026 revenue, surpassing Humira's peak and easing the post-Humira transition.

• CHMP Wins for RINVOQ: AbbVie (NYSE: ABBV) received positive CHMP opinions for RINVOQ in severe alopecia areata and non-segmental vitiligo.

• Strong Lymphoma Data: Phase 3 EPCORE DLBCL-4 data showed epcoritamab plus lenalidomide cut progression risk by up to 60%.

AbbVie Inc. (NYSE: ABBV) shares are trading modestly lower but holding near 52-week highs, supported by a wave of positive pipeline catalysts that have energized investor sentiment. The modest daily pullback comes against a backdrop of broadly strong momentum for the name.

The headline development is a milestone for the company's transition beyond its former blockbuster. Skyrizi hit $4.5 billion in first-quarter 2026 revenue, surpassing Humira's peak. That achievement is significant because the post-Humira transition, as Humira faced biosimilar competition, has been a central question for AbbVie investors for years.

Humira was long one of the best-selling drugs in the world, and its loss of exclusivity created a revenue gap that AbbVie needed to fill. Skyrizi surpassing Humira's peak revenue signals that the company's next-generation immunology franchise has successfully stepped into that role. The post-Humira transition increasingly looks resolved, a major de-risking for the investment case.

The pipeline momentum extends further. AbbVie (NYSE: ABBV) received back-to-back positive CHMP opinions from the European Medicines Agency for RINVOQ in both severe alopecia areata and non-segmental vitiligo. Positive CHMP opinions are an important step toward European approval and can expand a drug's addressable indications.

RINVOQ is another pillar of AbbVie's immunology strategy, and each new indication broadens its commercial potential. Adding severe alopecia areata and non-segmental vitiligo to its potential label set would extend RINVOQ's reach into additional patient populations.

The oncology pipeline also delivered strong data. Phase 3 results from the EPCORE DLBCL-4 trial showed that epcoritamab plus lenalidomide cut lymphoma progression risk by up to 60%. A progression-risk reduction of that magnitude is a compelling clinical result and strengthens AbbVie's position in blood cancers.

Together, these catalysts paint a picture of a company firing on multiple cylinders: a resolved Humira transition, an expanding immunology franchise led by Skyrizi and RINVOQ, and encouraging oncology data. That breadth is part of what has kept the stock near 52-week highs.

The broader sector backdrop has helped as well. The XLV healthcare ETF is trading near its 52-week high, reflecting a rotation into healthcare amid tech volatility. That defensive bid has provided a supportive environment for large-cap pharma names like AbbVie.

The modest daily dip should be viewed in context. After a strong run to near 52-week highs on the back of multiple positive catalysts, small pullbacks are routine and do not necessarily signal a change in the underlying trajectory.

For investors tracking AbbVie (NYSE: ABBV), the key items to watch include continued Skyrizi and RINVOQ growth, European regulatory decisions following the CHMP opinions, further oncology data, and whether the healthcare sector rotation persists. With the Humira overhang increasingly behind it, AbbVie's story has shifted toward the growth of its next-generation franchises. This article is for informational purposes only and is not investment advice.

()